Heart attack patients who stop statin risk death, say researchers

Aug 27, 2008

Patients discontinuing statin medication following an acute myocardial infarction (AMI) increase their risk of dying over the next year, say researchers at McGill University and the McGill University Health Centre (MUHC). Their study was published in a recent issue of the European Heart Journal.

Using data on British patients who survived an AMI and were still alive three months later, Dr. Stella Daskalopoulou and colleagues found that those who discontinued their statin medication were 88% more likely to die during the following year compared to those who had never been on the medication.

"Statins were found to be beneficial drugs," said Dr. Daskalopoulou, of McGill's Faculty of Medicine and the Department of Medicine and the Division of Clinical Epidemiology at the MUHC. "Patients who used statins before an AMI and continued to take them after were 16% less likely to die over the next year than those who never used them. So even if it appears that the statins failed to prevent your AMI, it is beneficial to continue taking them and potentially quite harmful to stop."

The large, population-based cohort study was conducted using UK data to take advantage of the medical records kept in the General Practice Research Database (GPRD), which collects information on the health of more than three million patients across the UK.

"In the general population the statin discontinuation rate within the first year of prescription is 30 percent. That's very high," Dr. Daskalopoulou continued. "Because statins are preventative drugs, patients may not feel the immediate benefit of taking them and sometimes stop. However, it looks like this might be quite a dangerous practice after an AMI."

The harmful effects of statin discontinuation may be the result of many different mechanisms, including individual patient characteristics, the researchers explained. "Regardless of the mechanism or explanation, physicians should be careful when assessing each patient's medication needs," Dr. Daskalopoulou said. "Patients also need to take their medications exactly as prescribed after an AMI. Statins in particular should only be withdrawn after an AMI under close clinical supervision."

Source: McGill University

Explore further: Experimental Ebola drugs must be fairly distributed and tested ethically in clinical trials

add to favorites email to friend print save as pdf

Related Stories

Study finds gender gap persists in cardiac care

Dec 09, 2009

Gender differences persist in the quality of cardiac care across Ontario, according to a health study by researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES). Ontario women who had ...

Recommended for you

Nigeria confirms two new Ebola cases (Update)

2 hours ago

Two new cases of Ebola have emerged in Nigeria and, in an alarming development, they are outside the group of caregivers who treated an airline passenger who arrived with Ebola and died, Health Minister Onyebuchi ...

Senegal closes border as UN warns on Ebola flare-up

6 hours ago

Senegal has become the latest country to seal its border with a west African neighbour to ward off the deadly Ebola virus, as the new UN pointman on the epidemic said preparations must be made for a possible flare-up of the ...

Climate change could see dengue fever come to Europe

6 hours ago

Dengue fever could make headway in popular European holiday destinations if climate change continues on its predicted trajectory, according to research published in open access journal BMC Public Health.

American Ebola doc: 'I am thrilled to be alive'

14 hours ago

Calling it a "miraculous day," an American doctor infected with Ebola left his isolation unit and warmly hugged his doctors and nurses on Thursday, showing the world that he poses no public health threat ...

User comments : 0